Expansion of Neurology Product Portfolio
Tachra Pharmaceutical Group, aiming to expand its neurology product portfolio, has for the first time in Iran produced VinciMind® in two therapeutic dosages. This initiative is intended to improve the quality of life for patients suffering from brain and neurological disorders.
The product was officially unveiled at the International Neurology Congress held at the Razi Conference Center in May 2025, showcased at the Tachra Pharmaceutical Group’s booth.
For the full news article, click here to visit Pharmondays website.
